
Releases
Immunic Executives Schedule July Investor Circuit
Executives from Immunic, Inc. will fan out across three major investor forums this July to detail the company’s late-stage clinical progress. The leadership team plans to engage with stakeholders in Boston and San Francisco, highlighting the ongoing phase 3 trials for their lead neurologic therapy, vidofludimus calcium.

























